Table 3.
Baseline characteristics of patients with osteoporosis according to the TSH suppression.
| TSH Suppression (−) | TSH Suppression (+) | p-Value | |
|---|---|---|---|
| N | 100 | 39 | |
| Age (years) | 61.0 ± 8.0 | 60.0 ± 8.0 | 0.857 |
| BMI (kg/m2) | 23.6 ± 3.1 | 24.6 ± 4.3 | 0.126 |
| Diabetes mellitus, n (%) | 25 (25.0) | 8 (20.5) | 0.576 |
| a Medications for osteoporosis | 0.523 | ||
| Bisphosphonate | 89 (89.0) | 34 (87.2) | |
| Denosumab | 24 (24.0) | 8 (20.5) | |
| SERM/HRT | 50 (50.0) | 14 (35.9) | |
| Cancer type: PTC, n (%) | 94 (94.0) | 34 (87.2) | 0.181 |
| Extent of surgery: Total thyroidectomy, n (%) |
97 (89.9) | 28 (71.8) | <0.001 |
| b Mean TSH (mIU/L) | 2.51 ± 1.43 | 0.32 ± 0.25 | <0.001 |
| Laboratory test at the time of diagnosis (pre-operative time) | |||
| TSH (mIU/L) | 2.15 ± 4.57 | 2.95 ± 4.02 | 0.313 |
| Free T4 (ng/dL) | 1.32 ± 0.18 | 1.24 ± 0.21 | 0.050 |
| Calcium (mg/dL) | 9.00 ± 0.66 | 8.92 ± 0.43 | 0.434 |
| Phosphate (mg/dL) | 3.78 ± 0.64 | 3.83 ± 0.53 | 0.657 |
| ALP (IU/L) | 60.96 ± 19.82 | 63.97 ± 30.25 | 0.567 |
| 25OHD (ng/mL) | 25.11 ± 18.84 | 20.83 ± 14.43 | 0.193 |
| iPTH (pg/mL) | 23.12 ± 14.88 | 21.59 ± 12.56 | 0.587 |
a Medications for osteoporosis, patients who received more than one type of medication were counted by each type of medication. b Mean TSH, the integral value of TSH over time divided by the total follow-up period. Values are presented as mean ± standard deviation for continuous variables. Comparisons between the two groups were made using the parametric Student t-test. Abbreviations: BMI, body mass index; PTC, papillary thyroid carcinoma; SERM, selective estrogen receptor modulator; HRT, hormone replacement therapy; 25OHD, 25-hydroxy vitamin D3; iPTH, intact PTH; ALP, alkaline phosphatase.